Search research articles
Contact Us
Filters
Showing results (1-10 of 126) with videos related to
Page
of 13
Sort By:
Hematology. American Society of Hematology. Education Program
|
December 10, 2021
Oral hypomethylating agents: beyond convenience in MDS
Elizabeth A Griffiths
Current Opinion in Hematology
|
November 20, 2023
Transfusion avoidance in myelodysplastic neoplasms
Elizabeth A Griffiths
Clinical Advances in Hematology & Oncology : H&O
|
December 30, 2025
Ravulizumab-danicopan combination therapy in PNH management
Elizabeth A Griffiths
Leukemia & Lymphoma
|
April 10, 2008
DNA methyltransferase inhibitors: class effect or unique agents?
Elizabeth A Griffiths, Steven D Gore
Blood Reviews
|
April 1, 2018
To chelate or not to chelate in MDS: That is the question!
Amer M Zeidan, Elizabeth A Griffiths
Blood
|
June 23, 2009
MicroRNA: mIR-ly regulators of DNMT?
Elizabeth A Griffiths, Steven D Gore
Lancet (London, England)
|
April 28, 2023
FLT3-mutated acute myeloid leukaemia: a new opportunity
Amanda C Przespolewski, Elizabeth A Griffiths
Cancer Cell
|
July 9, 2021
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution
Elizabeth A Griffiths, Brahm H Segal
Advances in Experimental Medicine and Biology
|
September 8, 2012
Epigenetic therapies in MDS and AML
Elizabeth A Griffiths, Steven D Gore
Blood Reviews
|
February 8, 2020
BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting
Amanda C Przespolewski, Elizabeth A Griffiths
Page
of 13
Search research articles
Search
Showing results (1-10 of 126) with videos related to
Sort By:
Page
of 13
Hematology. American Society of Hematology. Education Program
|
December 10, 2021
Oral hypomethylating agents: beyond convenience in MDS
Elizabeth A Griffiths
Current Opinion in Hematology
|
November 20, 2023
Transfusion avoidance in myelodysplastic neoplasms
Elizabeth A Griffiths
Clinical Advances in Hematology & Oncology : H&O
|
December 30, 2025
Ravulizumab-danicopan combination therapy in PNH management
Elizabeth A Griffiths
Leukemia & Lymphoma
|
April 10, 2008
DNA methyltransferase inhibitors: class effect or unique agents?
Elizabeth A Griffiths, Steven D Gore
Blood Reviews
|
April 1, 2018
To chelate or not to chelate in MDS: That is the question!
Amer M Zeidan, Elizabeth A Griffiths
Blood
|
June 23, 2009
MicroRNA: mIR-ly regulators of DNMT?
Elizabeth A Griffiths, Steven D Gore
Lancet (London, England)
|
April 28, 2023
FLT3-mutated acute myeloid leukaemia: a new opportunity
Amanda C Przespolewski, Elizabeth A Griffiths
Cancer Cell
|
July 9, 2021
Immune responses to COVID-19 vaccines in patients with cancer: Promising results and a note of caution
Elizabeth A Griffiths, Brahm H Segal
Advances in Experimental Medicine and Biology
|
September 8, 2012
Epigenetic therapies in MDS and AML
Elizabeth A Griffiths, Steven D Gore
Blood Reviews
|
February 8, 2020
BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting
Amanda C Przespolewski, Elizabeth A Griffiths
Page
of 13